These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1829912)
1. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Crippa F; Buraggi GL; Di Re E; Gasparini M; Seregni E; Canevari S; Gadina M; Presti M; Marini A; Seccamani E Eur J Cancer; 1991; 27(6):724-9. PubMed ID: 1829912 [TBL] [Abstract][Full Text] [Related]
4. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. van Zanten-Przybysz I; Molthoff CF; Roos JC; Verheijen RH; van Hof A; Buist MR; Prinssen HM; den Hollander W; Kenemans P Int J Cancer; 2001 Apr; 92(1):106-14. PubMed ID: 11279613 [TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal 131I- and 111In-791T/36 monoclonal antibody in recurrent ovarian cancer: imaging and biodistribution. Perkins AC; Pimm MV; Gie C; Marksman RA; Symonds EM; Baldwin RW Nucl Med Commun; 1989 Aug; 10(8):577-84. PubMed ID: 2812640 [TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. Gadina M; Canevari S; Ripamonti M; Mariani M; Colnaghi MI Int J Rad Appl Instrum B; 1991; 18(4):403-8. PubMed ID: 1864729 [TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696 [TBL] [Abstract][Full Text] [Related]
8. Biodistribution, pharmacokinetics and imaging of 131I-labelled OC125 in ovarian cancer. Haisma HJ; Moseley KR; Battaile AI; Griffiths TC; Zurawski VR; Knapp RC Int J Cancer Suppl; 1988; 2():109-13. PubMed ID: 3162437 [TBL] [Abstract][Full Text] [Related]
9. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Schlom J; Siler K; Colcher D; Carrasquillo JA; Reynolds JC; Sugarbaker P; Larson SM Acta Radiol Suppl; 1990; 374():123-8. PubMed ID: 1966958 [TBL] [Abstract][Full Text] [Related]
10. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Molthoff CF; Prinssen HM; Kenemans P; van Hof AC; den Hollander W; Verheijen RH Cancer; 1997 Dec; 80(12 Suppl):2712-20. PubMed ID: 9406729 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770 [TBL] [Abstract][Full Text] [Related]
12. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Coliva A; Zacchetti A; Luison E; Tomassetti A; Bongarzone I; Seregni E; Bombardieri E; Martin F; Giussani A; Figini M; Canevari S Cancer Immunol Immunother; 2005 Dec; 54(12):1200-13. PubMed ID: 15926078 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments. Barzen G; Mayr AC; Langer M; Becker R; Cordes M; Zwicker C; Koppenhagen K; Felix R Eur J Nucl Med; 1989; 15(1):42-8. PubMed ID: 2917583 [TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of radioimmunoimaging with 131I-C0C183B2 monoclonal antibody against ovarian carcinoma by intraperitoneal injection. Qian H; Feng J; Cui H; Gao B; Qi G; Fu T; Wei P; Fu Z Gynecol Oncol; 1992 Nov; 47(2):216-22. PubMed ID: 1468700 [TBL] [Abstract][Full Text] [Related]
16. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Colcher D; Esteban J; Carrasquillo JA; Sugarbaker P; Reynolds JC; Bryant G; Larson SM; Schlom J Cancer Res; 1987 Aug; 47(15):4218-24. PubMed ID: 3607761 [TBL] [Abstract][Full Text] [Related]
17. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070 [TBL] [Abstract][Full Text] [Related]
18. [Biodistribution, pharmacokinetics and imaging of 131I-labeled HMD4 human McAb in human ovarian carcinoma xenograft in nude mice]. Cui H Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):80-3, 123. PubMed ID: 2364795 [TBL] [Abstract][Full Text] [Related]
19. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer. Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619 [TBL] [Abstract][Full Text] [Related]
20. The detection of ovarian cancer using 123J monoclonal antibody. Granowska M; Britton KE; Shepherd J Radiobiol Radiother (Berl); 1984; 25(1):153-60. PubMed ID: 6729079 [No Abstract] [Full Text] [Related] [Next] [New Search]